Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK

Pigment Cell and Melanoma Research

Volumn 28, Issue 3, 2015, Pages 307-317

  Vogel, Celia J ^a   Smit, Marjon A ^a,i   Maddalo, Gianluca ^b,c   Possik, Patricia A ^a   Sparidans, Rolf W ^d   van der Burg, Sjoerd H ^e   Verdegaal, Els M ^e   Heck, Albert J R ^b,f   Samatar, Ahmed A ^g   Beijnen, Jos H ^h   Altelaar, A F Maarten ^b,f   Peeper, Daniel S ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c STOCKHOLM UNIVERSITY   (Sweden)

^d UTRECHT UNIVERSITY   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f NETHERLANDS PROTEOMICS CENTRE   (Netherlands)

^g TheraMet Biosciences   (United States)

^h SLOTERVAART HOSPITAL   (Netherlands)

ⁱ UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

MEK; ROCK; Melanoma; NRAS; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; FASUDIL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N RAS PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN; PUMA PROTEIN; SCH 772984; TRAMETINIB; UNCLASSIFIED DRUG; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NRAS PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEOME; RHO KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME PHOSPHORYLATION; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL LINE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SURVIVAL TIME; TUMOR VOLUME; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; GTP PHOSPHOHYDROLASES; HUMANS; MELANOMA; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; PROTEIN KINASE INHIBITORS; PROTEOME; RHO-ASSOCIATED KINASES;

EID: 84926676538     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12364     Document Type: Article

References (46)

1. Alhosin, M., Sharif, T., Mousli, M., Etienne-Selloum, N., Fuhrmann, G., Schini-Kerth, V.B., and Bronner, C. (2011). Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties. J. Exp. Clin. Cancer Res. 30, 41.
2. Altelaar, A.F.M., Munoz, J., and Heck, A.J.R. (2013). Next-generation proteomics: towards an integrative view of proteome dynamics. Nat. Rev. Gen. 14, 35-48.
3. Amano, M., Nakayama, M., and Kaibuchi, K. (2010). Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton 67, 545-554.
4. Arima, Y., Hirota, T., Bronner, C., Mousli, M., Fujiwara, T., Niwa, S., Ishikawa, H., and Saya, H. (2004). Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition. Genes Cells 9, 131-142.
5. Aronov, A.M., Tang, Q., Martinez-Botella, G. et al. (2009). Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. J. Med. Chem. 52, 6362-6368.
6. Ascierto, P.A., Schadendorf, P.D., Berking, C. et al. (2013). MEK162 for patients with advanced melanoma harbouring. Lancet Oncol. 14, 249-256.
7. Chapman, P.B., Hauschild, A., Robert, C. et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
8. Chun, K.H., Choi, K.D., Lee, D.H., Jung, Y., Henry, R.R., Ciaraldi, T.P., and Kim, Y.B. (2011). In vivo activation of ROCK1 by insulin is impaired in skeletal muscle of humans with type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 300, E536-E542.
9. Croft, D.R., Sahai, E., Mavria, G., Li, S., Tsai, J., Lee, W.M.F., Marshall, C.J., and Olson, M.F. (2004). Conditional ROCK activation in vivo induces tumor cell dissemination and angiogenesis. Cancer Res. 64, 8994-9001.
10. Diaz, L.A., Williams, R.T., Wu, J. et al. (2012). The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540.
11. Dry, J.R., Pavey, S., Pratilas, C.A. et al. (2010). Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 70, 2264-2273.
12. Eggermont, A.M., Spatz, A., and Robert, C. (2014). Cutaneous melanoma. Lancet 383, 816-827.
13. Fedorenko, I.V., Gibney, G.T., and Smalley, K.S.M. (2013). NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene 32, 3009-3018.
14. Feng, Y., Barile, E., De, S.K. et al. (2011). Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-kB pathways. Pigment Cell Melanoma Res. 24, 703-713.
15. Frederick, D.T., Piris, A., Cogdill, A.P. et al. (2013). BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19, 1225-1231.
16. Gilmartin, A.G., Bleam, M.R., Groy, A. et al. (2011). GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. 17, 989-1000.
17. Hauschild, A., Grob, J.-J., Demidov, L.V. et al. (2012). Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365.
18. Held, M.A., Langdon, C.G., Platt, J.T. et al. (2013). Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov. 3, 52-67.
19. Imaoka, H., Toiyama, Y., Saigusa, S. et al. (2015). RacGAP1 expression, increasing tumor malignant potential, as a predictive biomarker for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis 36, 346-354.
20. Ji, Z., Flaherty, K.T., and Tsao, H. (2012). Targeting the RAS pathway in melanoma. Trends Mol. Med. 18, 27-35.
21. Karnoub, A.E., and Weinberg, R.A. (2008). Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 9, 517-531.
22. Liang, Y., Liu, M., Wang, P., Ding, X., and Cao, Y. (2013). Analysis of 20 genes at chromosome band 12q13: RACGAP1 and MCRS1 overexpression in nonsmall-cell lung cancer. Genes Chromosom. Cancer 52, 305-315.
23. Machida, Y.J., Machida, Y., Chen, Y., Gurtan, A.M., Kupfer, G.M., D'Andrea, A.D., and Dutta, A. (2006). UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol. Cell 23, 589-596.
24. Matthews, H.K., Delabre, U., Rohn, J.L., Guck, J., Kunda, P., and Baum, B. (2012). Changes in Ect2 localization couple actomyosin-dependent cell shape changes to mitotic progression. Dev. Cell 23, 371-383.
25. Mendoza, M.C., Er, E.E., and Blenis, J. (2011). The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 36, 320-328.
26. Morris, E.J., Jha, S., Restaino, C.R. et al. (2013). Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 3, 742-750.
27. Nakajima, M., Hayashi, K., Egi, Y. et al. (2003). Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma. Cancer Chemother. Pharmacol. 52, 319-324.
28. Ostrem, J.M., Peters, U., Sos, M.L., Wells, J.A., and Shokat, K.M. (2014). K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548-551.
29. Packer, L.M., East, P., Reis-Filho, J.S., and Marais, R. (2009). Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Pigment Cell Melanoma Res. 22, 785-798.
30. Patel, R.A., Forinash, K.D., Pireddu, R., Sun, Y., Sun, N., Martin, M.P., Schonbrunn, E., Lawrence, N.J., and Sebti, S.M. (2012). RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res. 72, 5025-5034.
31. Posch, C., Moslehi, H., Feeney, L. et al. (2013). Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc. Natl Acad. Sci. USA 110, 4015-4020.
32. Rath, N., and Olson, M.F. (2012). Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. EMBO Rep. 13, 900-908.
33. Rebecca, V.W., Alicea, G.M., Paraiso, K.H.T., Lawrence, H., Gibney, G.T., and Smalley, K.S.M. (2014). Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pigment Cell Melanoma Res. 27, 1154-1158.
34. Robert, C., Karaszewska, B., Schachter, J. et al. (2015). Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30-39.
35. Routhier, A., Astuccio, M., Lahey, D. et al. (2010). Pharmacological inhibition of Rho-kinase signaling with Y-27632 blocks melanoma tumor growth. Oncol. Rep. 23, 861-867.
36. Sahai, E., Olson, M.F., and Marshall, C.J. (2001). Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J. 20, 755-766.
37. Sebbagh, M., Renvoize, C., Hamelin, J., Riche, N., Bertoglio, J., and Breard, J. (2001). Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat. Cell Biol. 3, 346-352.
38. Smit, M.A., Maddalo, G., Greig, K., Raaijmakers, L.M., Possik, P.A., van Breukelen, B., Cappadona, S., Heck, A.J., and Altelaar, A.M., Peeper, D.S. (2014). ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma. Mol. Syst. Biol. 10, 772.
39. Sosman, J.A., Kittaneh, M., Lolkema, M.P.J.K., Postow, M.A., Schwartz, G., Franklin, C., Matano, A., Bhansali, S., Parasuraman, S., and Kim, K. (2014). A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: early encouraging clinical activity. ASCO Meet. Abstr. 32, 9009.
40. Street, C.A., and Bryan, B.A. (2011). Rho Kinase Proteins-Pleiotropic modulators of cell survival and apoptosis. Anticancer Res. 31, 3645-3658.
41. Ueki, T., Park, J.-H., Nishidate, T., Kijima, K., Hirata, K., Nakamura, Y., and Katagiri, T. (2009). Ubiquitination and downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells. Cancer Res. 69, 8752-8760.
42. Vizcaino, J.A., Cote, R.G., Csordas, A. et al. (2012). The Proteomics Identifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res. 41, D1063-D1069.
43. Vredeveld, L.C.W., Possik, P.A., Smit, M.A. et al. (2012). Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 26, 1055-1069.
44. Vujic, I., Posch, C., Sanlorenzo, M. et al. (2014). Mutant NRASQ61 shares signaling similarities across various cancer types-potential implications for future therapies. Oncotarget 5, 7936-7944.
45. Walia, V., Mu, E.W., Lin, J.C., and Samuels, Y. (2012). Delving into somatic variation in sporadic melanoma. Pigment Cell Melanoma Res. 25, 155-170.
46. Zhou, L., Zhao, X., Han, Y., Lu, Y., Shang, Y., Liu, C., Li, T., Jin, Z., Fan, D., and Wu, K. (2013). Regulation of UHRF1 by miR-146a/b modulates gastric cancer invasion and metastasis. FASEB J. 27, 4929-4939.